Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Squamous Cell Carcinoma of Head and Neck

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Squamous Cell Carcinoma of Head and Neck in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.

Research Excerpts

ExcerptRelevanceReference
"Head and neck squamous cell carcinoma (HNSCC) is an aggressive and often fatal disease."1.46Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. ( Ben-Jonathan, N; Kumar, B; Kumar, P; Takiar, V; Tuttle, TR, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tuttle, TR1
Takiar, V1
Kumar, B1
Kumar, P1
Ben-Jonathan, N1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Squamous Cell Carcinoma of Head and Neck

ArticleYear
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
    Cancer letters, 2017, 03-28, Volume: 389

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Carcinoma, Squamous Cell

2017